Empasiprubart

DB16469InvestigationalProtein Based Therapies

Empasiprubart is a humanized sweeping antibody designed to bind to C2, a protein in the complement cascade that leads to cell destruction when activated.

Mechanism: ARGX-117 binds to and inhibits the function of the C2 protein, and subsequently, its complement activation. This compound has the potential to augment inflammation and associated adaptive immune responses, which may aid in autoimmunity effects.
Curator reviewed
Code names: ARGX-117

Resolves to

Compound

UNIIPVA73UA67LCAS2579031-19-7

Targets

P06681C2

Transporters

P55899FCGRT

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1TransporterSubstrate / inhibitor direction, not just membership

Listed above

15Clinical trialsPhase, status and sponsor resolved per trial

7+ReferencesStructured and connected to the statements they support

Which drugs share a target with Empasiprubart, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account